PT  - JOURNAL ARTICLE
AU  - OLLIKAINEN, RIINA K.
AU  - SIPPOLA, ANTTI
AU  - TURPEENNIEMI-HUJANEN, TAINA
AU  - KUITUNEN, HANNE
AU  - PORVARI, KATJA
AU  - HAAPASAARI, KIRSI-MARIA
AU  - KUUSISTO, MILLA E.L.
AU  - KLAAVUNIEMI, TUULA
AU  - KUITTINEN, OUTI
TI  - Patient’s HLA Genotype Is Associated With the Risk of Central Nervous System Dissemination and Clinical Disease Presentation in Diffuse Large B-cell Lymphoma
AID  - 10.21873/anticanres.17143
DP  - 2024 Aug 01
TA  - Anticancer Research
PG  - 3255--3259
VI  - 44
IP  - 8
4099  - http://ar.iiarjournals.org/content/44/8/3255.short
4100  - http://ar.iiarjournals.org/content/44/8/3255.full
SO  - Anticancer Res2024 Aug 01; 44
AB  - Background/Aim: Central nervous system (CNS) involvement in aggressive B-cell lymphoma, either as a primary or secondary event to systemic disease, portends a poor prognosis. This study sought to identify patients at high risk for CNS relapse by analyzing their human leukocyte antigen (HLA) genotypes. Patients and Methods: We retrospectively examined the HLA genotypes of 164 patients with systemic lymphoma, primary CNS lymphoma, and CNS relapse of systemic lymphoma. Patient records were analyzed, and HLA typing was performed by the Finnish Red Cross Blood Service. After excluding patients who received CNS prophylaxis, 131 patients were included in the final analysis. Results: A strong association was found between the HLA-A*31 genotype and CNS disease (p=0.001). Additionally, various HLA genotypes were linked to lactate dehydrogenase levels, extranodal disease, International Prognostic Index score, and disease stage. Conclusion: The patient’s genetic constitution, rather than solely disease-related factors, plays a role in the tropism of lymphoma for the CNS. If confirmed in a larger study, defining the HLA genotype of a lymphoma patient could provide valuable information for predicting CNS relapse.